A Daily GLP-1 Pill Could Curb Heavy Drinking

Key Points:

• A small randomized trial by the University of Colorado Anschutz found that daily oral semaglutide, a GLP-1 drug, reduced heavy drinking days and alcohol-related negative consequences in people with moderate to severe alcohol use disorder (AUD).
• Although semaglutide did not significantly reduce alcohol cravings or average drinks per day, it helped participants drink less heavily and more moderately on drinking days.
• The study suggests oral semaglutide could be a convenient alternative to injectable forms and may serve as an effective harm reduction tool for AUD, potentially outperforming existing FDA-approved medications.
• The trial was limited by its small size and low semaglutide dose, with questions remaining about long-term effects, optimal dosing, and whether benefits extend to non-obese individuals or other substance use such as cannabis.
• Larger and longer clinical trials are currently underway to confirm these findings and clarify the role of GLP-1 therapies in treating alcohol and possibly other substance use disorders.